Is the efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts influenced by receptor levels , activation status , and heterodimerization?
The effective use of EGFR-specific antibodies in glioma will depend on identifying tumors with activated EGFR. The combination of EGFR and Src inhibitors may be an effective strategy for the treatment of glioma.
The number of valves requiring redo surgery does not negatively impact early or late survival. Mortality is not different whether one or multiple valves need to be tackled in a redo scenario.